孟鲁司特钠对小于5岁咳嗽变异性哮喘患儿EOS及血清总IgE水平的影响

目的观察孟鲁司特钠对〈5岁咳嗽变异性哮喘患儿外周血嗜酸性粒细胞计数及血清总IgE水平变化的影响。方法将2011年l-12月我科门诊入选的67例咳嗽变异性哮喘患儿，随机分为两组，30例为对照组给予常规的治疗，而观察组37例则在常规治疗的基础上给予孟鲁司特钠治疗。治疗前后分别测定患儿外周血嗜酸性粒细胞计数及血清总IgE。结果对照组治疗前后外周血嗜酸性粒细胞计数分别为（0．91±0．35）×109／L、（0．74±0．21）×10^9／L：治疗组治疗前后血嗜酸性粒细胞计数分别为（O：79±0．14）×109／L、（0．42±0.07）×10^9／L，治疗前后比较差异有高度统计学意义（P〈0．01）；对照组治疗前后血清总IgE水平分别为（90．17±14．06）、（88．65±18．13）IU／mL：治疗组治疗前后血清总IgE水平分别为（89．34±10．24）、（86．32±7．19）IU／mL，治疗前后比较差异有高度统计学意义（P〈0．01）：治疗3个月后两组比较差异有高度统计学意义（P〈0．01）。结论孟鲁司特钠疗效确切，依从性好，口服方便，可降低〈5岁咳嗽变异性哮喘患儿的血清总IgE水平，通过了解观察外周血嗜酸性粒细胞计数、血清总IgE水平的变化对咳嗽变异性哮喘的诊断治疗具有重要的临床指导意义。

Effects of Montelukast on serum immunoglobulin E and eosinophils in children with cough variant asthma under 5 years old

Objective To study the therapeutic effect of serum immunoglobulin E(IgE) and eosinophils(EOS) with Montelukast in children with cough variant asthma(CVA) under 5 years old.Methods 47 cases with cough variant asthma under 5 years old were divided into two groups at random.The control group were treated with routine therapy,the treatment group were treated with Montelukast based on routine therapy for 3 months.The IgE and EOS levels were determined before after treatment.Results Total effective rates in the treatment group and the control group were 78.37% and 43.33% respectively.The therapeutic efficacy in treatment group was significantly higher that in control group.Before and after treatment for 3 months,the EOS of control group were(0.91±0.35)×109/L and(0.74±0.21)×109/L respectively,the treatment group were(0.79±0.14)×109/L and(0.42±0.07)×109/L respectively.There was significant difference in EOS after treatment(P < 0.01).Before and after treatment for 3 months,the serum total IgE of control group was(90.17±14.06) IU/mL and(88.65±18.13) IU/mL respectively.As to the treatment group,the serum total IgE before and after treatment for 3 months was(89.34±10.24) IU/mL and(86.32±7.19) IU/mL respectively.There was significant difference in total IgE before and after treatment for 3 months(P < 0.01).Conclusion Taking oral Montelukast to treat the cough variant asthma has the definite curative effect,when treatment of children with cough variant asthma under 5 years old,Montelukast can decrease serum total IgE.Detection of IgE and EOS can be of great importance in diagnosis and treatment of children with cough variant asthma under 5 years old.